 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...979899100101102103104105106107...123124» |
- tacrolimus / Generic mfg., sirolimus / Generic mfg.
[VIRTUAL] Effects of immunosuppression and adjuvant immune-targeted drugs in preventing HCC recurrence after liver transplantation (E-Poster Hall) - Aug 29, 2020 - Abstract #TTS2020TTS_1484;
In conclusion, immunosuppression and immune-targeted durgs are feasible measures for preventing HCC recurrence of recipients for HCC-transplantation. Intervention like modulating dose of SRL/TAC and sorafenib/lenvatinib may help patients prevent recurrence and receive a better long-term prognosis.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] AGH score predicts recurrence and response to adjuvant-targeted therapy in HBV related HCC after liver transplantation. (E-Poster Hall) - Aug 29, 2020 - Abstract #TTS2020TTS_1339;
Intervention like modulating dose of SRL/TAC and sorafenib/lenvatinib may help patients prevent recurrence and receive a better long-term prognosis. AGH score may have the potential to serve as a predictor of recurrence and beneficiaries from targeted drug therapy in HBV related HCC patients following LT.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Genome-wide CRISPR/Cas9 library screening identified PAK1 as a critical driver for lenvatinib resistance in HCC. (Channel 7) - Aug 29, 2020 - Abstract #TTS2020TTS_494;
We conclude that the CRISPR screen is a powerful tool for therapeutic target analysis of lenvatinib treatment and that PAK1 serves as a druggable target for HCC treated with lenvatinib and an indicator of prognosis. In summary, our results demonstrate that targeting PAK1 is an effective approach to overcome lenvatinib drug resistance in HCC.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
P1 data: Richard Finn presents phase 1b data on lenvatinib + pembro in unresectable #HCC #ILC2020 (Twitter) - Aug 28, 2020
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Thalen: TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial (clinicaltrials.gov) - Aug 27, 2020
P=N/A, N=60, Recruiting, Sponsor: Yunfei Yuan
- || everolimus / Generic mfg., Fotivda (tivozanib) / AVEO, Jazz, Lenvima (lenvatinib) / Eisai, Merck (MSD)
consider lenvatinib/everolimus or (since I believe you may be able to access it?) tivozanib (Twitter) - Aug 27, 2020
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours (Channel 2) - Aug 27, 2020 - Abstract #ESMO2020ESMO_3425;
P2
and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT03797326.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004 (Channel 2) - Aug 27, 2020 - Abstract #ESMO2020ESMO_3406;
P2
Funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT03776136, originally posted on December 14, 2018.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Surgical treatment of a rare case of hepatocellular carcinoma with right atrial metastasis: A case report. (Pubmed Central) - Aug 27, 2020
These therapies have offered favorable clinical outcomes such as prevention of recurrence and prolongation of patient survival. In addition, clinicians may benefit from our experience for their future treatment of patients with similar clinical conditions.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: The mechanism of solvent-mediated desolvation transformation of lenvatinib mesylate from dimethyl sulfoxide solvate to form D. (Pubmed Central) - Aug 26, 2020
The overall desolvation transformation experiments demonstrated that the SMDT process was controlled by the nucleation and growth of form D. Moreover, effects of operating factors on the SMDT process were studied and the results illustrated that water activity in solution was the paramount parameter in the SMDT process. Finally, a new SMDT mechanism was suggested and discussed.
- || Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal: Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. (Pubmed Central) - Aug 26, 2020
Immunotherapy in HCC is a relatively safe option for treating patients with advanced disease in the USA who are either unable to receive or failed sorafenib/lenvatinib therapy and thus may offer an additional survival benefit for these patients. The purpose of this review is to elaborate on some of the most recent advancements in immunotherapy.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker: Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. (Pubmed Central) - Aug 26, 2020
LEP is a promising alternative as a non-first-line therapeutic regimen for patients with refractory BTC. Furthermore, well-designed prospective clinical trials with a control arm are still needed to obtain more evidences to confirm the efficacy and safety of this particular regimen as well as the role of PDL1 expression.
- ||| Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Clinical, Clinical guideline, Review, Journal, IO Biomarker: 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. (Pubmed Central) - Aug 26, 2020
Novel biomarkers, imaging and operative techniques are recommended in the updated Chinese guideline. More aggressive treatment modalities are suggested for more progressed HBV-related HCC in China.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] A PHASE 1/2 STUDY OF LENVATINIB (LEN) PLUS EVEROLIMUS (EVE) IN RECURRENT AND REFRACTORY PEDIATRIC SOLID TUMORS, INCLUDING CNS TUMORS (Hall 2) - Aug 26, 2020 - Abstract #SIOP2020SIOP_418;
Pharmacokinetic exposure was comparable to pediatric single-agent LEN and adults receiving LEN+EVE. Enrollment to the phase 2 portion is ongoing.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Aug 25, 2020
P2, N=40, Not yet recruiting, Sponsor: Shanghai Zhongshan Hospital
- ||| Clinical: Great references. Thank you. I can sense your excitement already for lenvatinib+pembro (vs lenvatinib+everolimus vs sunitinib). These Ph 3 studies were in the can before ipi-nivo, axi-pembro became SOC. We owe it to the pts to publish the data and cross-compare, no? (Twitter) - Aug 25, 2020
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Q&A Symposium: Cancer care beyond anti-tumor therapy () - Aug 25, 2020 - Abstract #ILCA2020ILCA_106;
LENVIMA® monotherapy in the rapidly evolving uHCC treatment landscape. This will include discussions around patient selection and clinical considerations in the first line setting as well as an overview of the latest clinical data for LENVIMA® monotherapy.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] The evolving HCC treatment landscape: what is the role of LENVIMA® monotherapy in first-line uHCC? () - Aug 25, 2020 - Abstract #ILCA2020ILCA_105;
In this symposium, Professor Andrew Zhu and Professor Arndt Vogel will discuss the role of LENVIMA® monotherapy in the rapidly evolving uHCC treatment landscape. This will include discussions around patient selection and clinical considerations in the first line setting as well as an overview of the latest clinical data for LENVIMA® monotherapy.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, P2 data, Clinical Trial,Phase II, Journal: Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. (Pubmed Central) - Aug 22, 2020
P2
Lenvatinib plus pembrolizumab showed promising anti-tumour activity with an acceptable safety profile in patients with advanced gastric cancer. On the basis of these results, a confirmatory trial will be planned in the future.
- | Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Combination therapy, Monotherapy: Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure. (Pubmed Central) - Aug 21, 2020
However, it remains unclear if failure to monotherapy has an impact on combination therapy. We therefore report a patient well responding to combination therapy despite previous failures to TKI and ICI monotherapy.
- ||| volrustomig (MEDI5752) / AstraZeneca
New P1 trial: A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Aug 20, 2020
P1b, N=52, Recruiting, Sponsor: MedImmune LLC
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
New P3 trial, Tumor mutational burden, IO biomarker, Metastases: JS001-027-III-HCC: Phase III Study of Toripalimab?JS001? Combined With Lenvatinib for Advanced HCC (clinicaltrials.gov) - Aug 20, 2020
P3, N=486, Recruiting, Sponsor: Shanghai Junshi Bioscience Co., Ltd.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Review article: new therapeutic interventions for advanced hepatocellular carcinoma. (Pubmed Central) - Aug 20, 2020
There are several first-line and second-line therapeutic options available for patients with advanced HCC. Further studies are needed to determine how best to select between and sequence the growing number of therapeutic options.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Summer is a time to be more aware of #skincancer. A Phase 3 Trial is being conducted by Dr. Omid Hamid @OmidHamidMD to evaluate #Pembrolizumab & #Lenvatinib vs pembrolizumab alone as first-line intervention for #melanoma @AngelesClinic #CedarsSinaiCancer https://t.co/LcjvmpJoCp (Twitter) - Aug 19, 2020
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Aug 19, 2020
P2, N=24, Not yet recruiting, Sponsor: Sheba Medical Center
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Effect of Lenvatinib on a Patient with Medullary Thyroid Carcinoma Liver Metastasis Caused by Multiple Endocrine Neoplasia Type 2A. (Pubmed Central) - Aug 18, 2020
The reduction rate of the MTC liver metastasis was 31%, which was considered partial response. At this point, the patient was doing well, suggesting that lenvatinib was effective in treating the MTC liver metastasis and may be one of the treatment for advanced MTC caused by C634Y mutation in the RET gene.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib and pembrolizumab in advanced gastric cancer. (Pubmed Central) - Aug 18, 2020
At this point, the patient was doing well, suggesting that lenvatinib was effective in treating the MTC liver metastasis and may be one of the treatment for advanced MTC caused by C634Y mutation in the RET gene. No abstract available
- | Journal: Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents. (Pubmed Central) - Aug 18, 2020
In addition, this research indicated that mTOR was correlated with the poor prognosis in patients with advanced HCC who received sorafenib. Our study identified a new type of small-molecular inhibitors of mTOR and confirmed their ability to enhance the antitumor effect of molecular-targeted agents on advanced HCC.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Pembro + Lenvatinib seems promising! (Twitter) - Aug 15, 2020
- || everolimus / Generic mfg., Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Retrospective data, Review, Journal: Second-line Treatments of Advanced Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Aug 14, 2020
Our study identified a new type of small-molecular inhibitors of mTOR and confirmed their ability to enhance the antitumor effect of molecular-targeted agents on advanced HCC. This network meta-analysis concludes that, based on current evidence, regorafenib could be the agent of choice in the second-line treatment of HCC, with cabozantinib as a possible alternative for sorafenib-intolerant patients.
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. (Pubmed Central) - Aug 14, 2020
Advanced hepatocellular carcinoma has limited treatment options, but there has been extensive growth recently with cabozantinib, regorafenib, lenvatinib, nivolumab, atezolizumab, and bevacizumab, which are some of the treatments that have received FDA approval just over the last three years...The anti-PD-1 checkpoint inhibitors nivolumab and pembrolizumab have been FDA approved as a second line treatment in patients who progressed or are intolerant to Sorafenib...Other novel immune-based approaches and oncolytic viruses are in the early phases of clinical evaluation. These innovative approaches enhance the intensity of cancer-directed immune responses and will potentially impact the outlook of this aggressive disease.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Metastases: A Study of E7080 in Subjects With Advanced Thyroid Cancer (clinicaltrials.gov) - Aug 14, 2020
P2, N=51, Completed, Sponsor: Eisai Co., Ltd.
These innovative approaches enhance the intensity of cancer-directed immune responses and will potentially impact the outlook of this aggressive disease. N=37 --> 51
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. (Pubmed Central) - Aug 13, 2020
Additionally, lenvatinib was independently associated with longer PFS time in patients with intermediate-stage HCC refractory to TACE. Therefore, lenvatinib may be recommended for patients who have intermediate-stage HCC refractory to TACE, ALBI grade 1 and who are within the up-to-seven criteria.
- || dovitinib (TKI258) / Oncology Venture, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal: Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors. (Pubmed Central) - Aug 13, 2020
Therefore, the aim of the present review is to describe the pharmacological characteristics of FGFR inhibitors that may be combined with other therapeutic agents and the preclinical data supporting their combination. Additionally, their clinical implications and the remaining challenges for FGFR inhibitor combination regimens are discussed.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia. (Pubmed Central) - Aug 13, 2020
Shunt occlusion prior to lenvatinib administration prevented hyperammonemia and hepatic encephalopathy. Shunt occlusion may be an effective treatment option to administer molecular target agents in patients with portosystemic shunts.
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
Trial completion date, Trial primary completion date: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - Aug 12, 2020
P3, N=300, Enrolling by invitation, Sponsor: BeiGene
Shunt occlusion may be an effective treatment option to administer molecular target agents in patients with portosystemic shunts. Trial completion date: Dec 2024 --> Dec 2021 | Trial primary completion date: Dec 2024 --> Dec 2021
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, PD(L)-1 Biomarker, IO biomarker: PLENTY202001: Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant (clinicaltrials.gov) - Aug 12, 2020
P=N/A, N=192, Recruiting, Sponsor: RenJi Hospital
Trial completion date: Dec 2024 --> Dec 2021 | Trial primary completion date: Dec 2024 --> Dec 2021 Active, not recruiting --> Recruiting
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: CheckMate 9DW: A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 10, 2020
P3, N=1084, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting Trial primary completion date: Sep 2023 --> Mar 2023
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: PLENTY202001: Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant (clinicaltrials.gov) - Aug 10, 2020
P=N/A, N=192, Active, not recruiting, Sponsor: RenJi Hospital
Trial primary completion date: Sep 2023 --> Mar 2023 Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2022
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors (clinicaltrials.gov) - Aug 9, 2020
P2, N=128, Recruiting, Sponsor: Shanghai Zhongshan Hospital
- | Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Journal: Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis. (Pubmed Central) - Aug 9, 2020
As a primary molecular-targeted agent-based treatment for advanced HCC, our findings suggested that sorafenib is generally appropriate as it offers significantly lower frequency of adverse events and higher probability of transition to secondary treatment, in consideration of the enhanced postprogression survival mediated by sequential treatment. Alternatively, lenvatinib affords a significantly higher therapeutic effect and should be used when immediate tumor reduction is required.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 8, 2020
P=N/A, N=713, Active, not recruiting, Sponsor: Eisai Inc.
Alternatively, lenvatinib affords a significantly higher therapeutic effect and should be used when immediate tumor reduction is required. Trial primary completion date: May 2021 --> Feb 2020
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, PK/PD data, Review, Journal: Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. (Pubmed Central) - Aug 7, 2020
Systemic therapy with TKIs is based on sorafenib and lenvatinib as first-line treatment and regorafenib and cabozantinib as second-line treatment...To date, only partial data supporting sorafenib monitoring is available. Results from further pharmacokinetic/pharmacodynamic studies of these four TKIs are eagerly awaited and are expected to permit such monitoring and the development of consensus guidelines.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Nasogastric administration of lenvatinib solution in a mechanically ventilated patient with rapidly growing anaplastic thyroid cancer. (Pubmed Central) - Aug 7, 2020
The lenvatinib solution was effective for a patient with difficulty in oral intake. Lenvatinib could also improve the prognosis of an anaplastic thyroid cancer patient with severe airway and esophageal trouble.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. (Pubmed Central) - Aug 7, 2020
A multivariate Cox proportional hazards model showed that modified albumin-bilirubin-grade (mALBI) 2b (hazard ratio (HR) 4.39) and a decreased GS (HR 3.55) were independently associated with an increased risk of poor prognosis. In addition to the hepatic functional reserve, a decreased GS was a poor prognostic factor in lenvatinib-treated u-HCC patients.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, PD(L)-1 Biomarker, Metastases: Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) (clinicaltrials.gov) - Aug 7, 2020
P2, N=34, Recruiting, Sponsor: Washington University School of Medicine
In addition to the hepatic functional reserve, a decreased GS was a poor prognostic factor in lenvatinib-treated u-HCC patients. Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 6, 2020
P2, N=54, Not yet recruiting, Sponsor: Shanghai Zhongshan Hospital
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal, IO biomarker: Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review. (Pubmed Central) - Aug 6, 2020
Several other emerging classes of medications, such as gene fusion inhibitors and immune checkpoint inhibitors, are being actively investigated in several clinical trials. In this review, we describe the molecular landscape of thyroid cancer and novel targeted therapies and treatment combinations available for the treatment of metastatic thyroid cancer.
- | Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal: Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. (Pubmed Central) - Aug 6, 2020
Three first-line (single-agent Sorafenib or Lenvatinib, and combination of Atezolizumab plus Bevacizumab) followed by five second-line treatments (Regorafenib, Cabozantinib, Ramucirumab, Nivolumab, Pembrolizumab) were compared in fifteen sequential strategies...Accordingly, the net health benefit assessed by ISER favored Lenvatinib followed by Nivolumab, compared to Atezolizumab plus Bevacizumab, followed by Nivolumab in 52% of cases. Further sequential clinical trials or large-scale real-world studies may prove useful to evaluate the net health benefit of the best sequential treatment for advanced HCC.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Clinical, Journal, Real-World Evidence: Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. (Pubmed Central) - Aug 4, 2020
Further sequential clinical trials or large-scale real-world studies may prove useful to evaluate the net health benefit of the best sequential treatment for advanced HCC. Good hepatic function (mALBI 1/2a) is the best indication for LEN, while potential appetite loss in association with low BMI should be kept in mind in such cases.